EGFR inhibition by anti-EGFR monoclonal antibodies (MAbs) or tyrosine kinase inhibitors (TKIs) represents a particularly successful molecular targeted therapy for tumors such as Non-Small Cell Lung Cancer and Colorectal Cancer. Here, EGFR is linked to non-small cell lung carcinoma.